HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancer

HER2CLIMB-04: tucatinib + trastuzumab deruxtecan in HER2+ breast cancerПодробнее

Tucatinib for the Treatment of HER2+ Breast CancerПодробнее

HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2+ breast cancer with brain metastasesПодробнее

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic...Подробнее

Choosing between tucatinib and T-DXd in HER2+ breast cancerПодробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

HER2CLIMB: tucatinib efficacious against brain metastases in patients with HER2+ breast cancerПодробнее

Tucatinib Combination Improved Survival in HER2–Positive Breast CancerПодробнее

HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumabПодробнее

HER2+ mBC: Systemic Therapies and HER2CLIMB-02 TrialПодробнее

HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BCПодробнее

The Benefits of Tucatinib in HER2+ Breast CancerПодробнее

Tucatinib in HER2+ breast cancer with leptomeningeal metastasesПодробнее

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain MetastasesПодробнее

Dr. Blackwell Discusses Tucatinib in HER2+ Breast CancerПодробнее

HER2CLIMB Regimen Can Be Used Earlier in HER2+ Metastatic Breast CancerПодробнее

Tucatinib Plus Trastuzumab & Capecitabine for Patients With HER2-Positive Breast Cancer & Brain MetsПодробнее

HER2CLIMB-02 Study Data Assesses Trastuzumab Plus Tucatinib in Patients With HER2+ Breast CancerПодробнее

HER2CLIMB-02: tucatinib + TDM-1 in advanced breast cancerПодробнее